Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Employees75,000SIC2834HQ126 East Lincoln Avenue, Rahway, NJ, USA, 07065
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
73.9%
Operating Margin
19.7%
EBITDA Margin
29.5%
Net Margin
13.6%
OCF Margin
27.2%
FCF Margin
21.5%
Returns on Capital
ROE
18.0%
ROA
7.1%
ROIC
11.2%
ROCE
13.4%
ROC (Greenblatt)
46.0%
3Y ROIIC
14.2%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
36.50
Forward P/E
24.98
P/E ex-NRI
23.69
Shiller P/E (CAPE)
31.93
Cash Flow Multiples
P/FCF
22.89
P/OCF
18.06
P/Owner Earnings
59.57
FCF Yield
4.41%
Enterprise Value Multiples
EV / EBIT
27.45
EV / Forward EBIT
26.18
EV / EBITDA
18.60
EV / Forward EBITDA
19.03
EV / Revenue
5.49
EV / Forward Revenue
5.41
Asset / Sales
P/S
4.91
P/B
6.97
P/Tangible Book
—
Growth-Adjusted
PEG
1.50
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.62%
Forward Dividend Yield
2.65%
3Y Dividend Growth
5.4%
Payout Ratio
0.61
5Y Yield on Cost
3.46%
Buybacks & Dilution
3Y Buyback Ratio
0.80%
Combined
Shareholder Yield
1.95%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
1.07
Gross Debt / EBITDA
2.53
Cash / Debt
0.12
Equity / Assets
0.36
Coverage
Interest Coverage
8.52
Short-Term Liquidity
Current Ratio
1.30
Quick Ratio
1.06
Cash Ratio
0.21
Composite Scores
Piotroski F-Score
4
Altman Z-Score
3.97
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-06-15
$0.85
2026-07-08
2026-03-16
$0.85
2026-04-07
2025-12-15
$0.85
2026-01-08
2025-09-15
$0.81
2025-10-07
2025-06-16
$0.81
2025-07-08
2025-03-17
$0.81
2025-04-07
2024-12-16
$0.81
2025-01-08
2024-09-16
$0.77
2024-10-07
2024-06-17
$0.77
2024-07-08
2024-03-14
$0.77
2024-04-05
10 of 45
View allDate
Transcript
Type
2026-08-04
Q2 2026 Merck & Co Inc Earnings Call Transcript
Earnings Call
2026-08-03
Merck & Co Inc at Investor Event at AIDS Transcript
Analyst/Investor Call
2026-06-09
Merck & Co Inc at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-06-04
Merck & Co Inc at Jefferies Global Healthcare Conference in New York Transcript
Conference Presentations
2026-06-01
Merck & Co Inc Investor Event at ASCO Transcript
Analyst/Investor Call
2026-05-26
Merck & Co Inc Annual Shareholders Meeting Transcript
Shareholders and Annual Meetings
2026-04-30
Q1 2026 Merck & Co Inc Earnings Call Transcript
Earnings Call
2026-03-25
Merck & Co Inc to Acquire Terns Pharmaceuticals Inc Transcript
Company Actions
2026-03-03
Merck & Co Inc at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-03
Q4 2025 Merck & Co Inc Earnings Call Transcript
Earnings Call
10 of 103
5-Step DuPont Analysis
ROE %
18.97%
×
×
Net Margin %
13.59%
×
×
Operating Margin %
19.72%
Operating Income
$12.97B
÷
Revenue
$65.77B
×
Tax Burden
0.7683
Net Income
$8.94B
÷
Pretax Income
$11.63B
×
Interest Burden
0.8967
Pretax Income
$11.63B
÷
Operating Income
$12.97B
×
Asset Turnover
0.54
÷
Revenue
$65.77B
÷
Average Total Assets
$121.90B
Begin Total Assets
$115.12B
End Total Assets
$128.69B
×
Equity Multiplier
2.59
÷
Avg Total Assets
$121.90B
÷
Avg Stockholders Equity
$47.11B
Begin Equity
$48.34B
End Equity
$45.88B